Amgen's claims related to antibodies aimed at PCSK9, Regeneron and Sanofi said in a statement. PCSK9 is a gene that gives instructions for producing a protein that aids in regulating cholesterol, according to the US National Library of Medicine.
"Today's decision by the U.S. District Court for the District of Delaware validates our position that Amgen's patents are overly broad and invalid," Joseph LaRosa, Regeneron's general counsel said in a statement.
Price: 287.64, Change: 0.00, Percent Change: 0.00
|Q4 Estimate for Vince Holding Lowered but Full Year ...|
|2020, 2021, and Q2 Earnings Estimates for United Nat...|
|LendingTree's 2020 Earnings Estimate Lowered|
|Total's Q4 and 2020, Estimates Raised but 2019 Earni...|
|Team's 2020 Earnings Projection Cut|